Endocrine

Prescribing of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2 inhibitors) and risk of Diabetic Ketoacidosis (including in patients with COVID-19)

NEW 'COVID-19 Q & A Document: Management of patients prescribed testosterone during the pandemic